Compare WPP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPP | MIRM |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | WPP | MIRM |
|---|---|---|
| Price | $22.38 | $78.82 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $92.45 |
| AVG Volume (30 Days) | 572.9K | ★ 813.7K |
| Earning Date | 08-07-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.44% | N/A |
| EPS Growth | ★ 86.47 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $19,423,208,660.00 | $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | N/A | $19.91 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $17.47 | $36.88 |
| 52 Week High | $52.26 | $82.58 |
| Indicator | WPP | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 61.40 | 62.89 |
| Support Level | $21.93 | $63.23 |
| Resistance Level | $22.28 | $82.58 |
| Average True Range (ATR) | 0.44 | 3.74 |
| MACD | 0.14 | 1.62 |
| Stochastic Oscillator | 86.22 | 81.03 |
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.